Targeted drug combination for lung cancer with brain spread
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial studies two targeted therapy drugs, furmonertinib and anlotinib, given together as a pill treatment. It is for people with a specific genetic change (EGFR mutation) in lung cancer that has spread to the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer is a type of lung cancer called non-small cell lung cancer, specifically adenocarcinoma (a common subtype).
- Your tumor has a specific gene change called an EGFR mutation, which can be found through a biopsy or blood test.
- You have at least one tumor that has spread to the brain and can be measured on a scan.
- You are generally able to care for yourself (ECOG score 0 or 1).
- You have not had any prior treatment for advanced lung cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
This trial tests a combination of a targeted pill (furmonertinib), chemotherapy into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR-mutant adenocarcinoma) that has spread to both the brain and the lining around the brain. The goal is to see if this combination can better control the cancer and improve symptoms.
This study tests two doses of furmonertinib (a targeted pill) combined with chemotherapy for people with a specific EGFR gene change in lung cancer that has spread to the brain. It aims to see if the higher dose works better while keeping side effects manageable.
This trial tests a strong dose of furmonertinib (a targeted pill) combined with two other drugs, bevacizumab and pemetrexed, for people with EGFR-mutated non-small cell lung cancer that has spread to the lining of the brain or spinal cord. It aims to see if this combination can better control the cancer and improve symptoms.
This trial tests a new way to give a targeted therapy (furmonertinib) to people with a specific type of lung cancer that has spread to the lining of the brain. It uses a higher, pulsing dose to try to get more medicine into the brain fluid and stop the cancer there.
This trial tests a combination of two targeted drugs (Furmonertinib and Avastin) as the very first treatment for people with a specific type of lung cancer (EGFR-mutant non-small cell) that has spread to the brain. The goal is to see how well it works and how safe it is.
Hear when a new Adenocarcinoma of Lung Metastatic to Brain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.